Antiretroviral naïve patients with <350 xE6/l CD4 cells and a HIV-viral load of > 30.000
cop/ml are started on combivir ® and Kaletra ®. When patients have reached an undetectable
viral load of< 50 cop/ml on two consecutive occasions at least at week 12, but no later than
week 24, they are randomised in either continuation with Combivir/Kaletra or switch to
Trizivir ® twice daily one pill during 96 weeks. All patients randomised in the
combivir/Kaletra arm are eligible to switch to Trizivir at any post randomisation visit when
they reach predefined switch criteria for elevated levels of fasting glucose or lipids.
Phase:
Phase 3
Details
Lead Sponsor:
Rijnstate Hospital
Collaborator:
GlaxoSmithKline
Treatments:
Abacavir Lamivudine Lamivudine, zidovudine drug combination Zidovudine